Please Wait...

Ronald Van Heertum

Translation skills

Main profile

Ronald Van Heertum, MD
Vice President of Molecular Imaging

Dr. Van Heertum is responsible for the management and implementation of all aspects of Molecular Imaging. Prior to coming to BioClinica, Dr. Van Heertum was Professor and Executive Vice Chairman/CAO, Department of Radiology at Columbia University College of Physicians & Surgeons as well as Director of Nuclear Medicine and PET. In this position he participated in many clinical trials in oncology, neurology, and psychiatry and established an international reputation in SPECT and PET imaging. He has authored or co-authored over 200 publications and is the editor of a book on Brain Imaging that is now in its 4th Edition. He has been an active member of the RSNA, American College of Radiology where he is an FACR and the Society of Nuclear Medicine.

Authored Publications

Van Heertum RL, Scarimbolo R, Wolodzko JG, Klencke B, Messmann R, Tunc F, Sokol L, Agarwal R, Strafaci JA, O'Neal M.  Lugano 2014 criteria for assessing FDG-PET/CT in lymphoma: an operational approach for clinical trials.  Dovepress.  13 June 2017 Volume 2017:11 Pages 1719—1728.

Van Heertum RL, Scarimbolo R, Ford R, Berdougo E, O’Neal M. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. Drug Design, Development and Therapy 2015:9 5215–5223.

Blogs

Brain scan

I recently returned from the 6th Annual Clinical Trials in Alzheimer's Disease (CTAD) conference in San Diego. At the meeting, I had a chance to catch up on some of the latest scientific advances for the detection and treatment of AD. A recurring theme for improving the diagnosis and prognosis of AD is the increased use of biomarker data.

What do you get when you combine a molecular diagnostic agent with a targeted therapeutic? A powerful new tool paving the path to personalized medicine called a Theranostic. The basic architecture of a theranostic is as follows:

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

RT @ACROhealth: @MaryWolleyRA Mary Woolley @ResearchAmerica: 80% have heard of #clinicaltrials. 75% think trial participation is as importa…
bioclinica (2 days ago)
#Pharma & CROs: Ck it out! Enterprise tools for site payments automation & reconciliation. https://t.co/LFri5Kv0WC
bioclinica (2 days ago)
Can having a geographically diverse network of high performing sites mean fewer sites are needed in a trial? Can ha… https://t.co/tZYvWrNzHg
bioclinica (2 days ago)
Confidence is a good thing ─ especially in the clinical supply chain for global clinical trials. Here’s how accurat… https://t.co/70VwXCwuWw
bioclinica (3 days ago)
#Pharmacovigilance: Get up-to-speed on latest ind. trends & best practices + hear how others R meeting today's most… https://t.co/3YNpB9hTXs
bioclinica (5 days ago)
Announcing our new Chief of Staff @bioclinica Adrienne Rossi! Also welcoming President Bioclinica Site Network Eliz… https://t.co/toB9yk534k
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen